Eli Lilly and Co (XSWX:LLY) FFO per Share


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF970.00
GF Value CHF1,111.71
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co FFO per Share?

FFO per Share only applies to REITs.

XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF970.00 is trading 12.7% below its estimated GF Value™ of CHF1,111.71. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • FFO per Share:
  • GF Value™: CHF1,111.71 vs. price of CHF970.00 (12.7% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF970.00
Price
CHF1,111.71
GF Value